Optimizing Informed Consent—A Call to Action
This Viewpoint discusses the US Food and Drug Administration’s proposal for a collaborative approach toward clarifying the informed consent process for potential clinical trial participants.
Authors
- Ann Meeker-O’Connell (ORCID: https://orcid.org/0000-0002-3772-7970)
- Nancy Kass (ORCID: https://orcid.org/0000-0003-3833-8456)
- Stephanie R. Morain (ORCID: https://orcid.org/0000-0001-7278-7517)
- Matthew A. Crane (ORCID: https://orcid.org/0000-0002-0529-8948)
Institutions
- Brigham and Women's Hospital (US)
- United States Food and Drug Administration (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Johns Hopkins Berman Institute of Bioethics (US)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1001/jamahealthforum.2025.0824
- Citations
- 3
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 5.64